GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Cyclically Adjusted Book per Share

Egetis Therapeutics AB (OSTO:PLED BTA) Cyclically Adjusted Book per Share : kr0.00 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted book value per share for the three months ended in Mar. 2025 was kr15.886. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Egetis Therapeutics AB's average Cyclically Adjusted Book Growth Rate was -3.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Egetis Therapeutics AB was 5.70% per year. The lowest was 4.70% per year. And the median was 5.00% per year.

As of today (2025-07-03), Egetis Therapeutics AB's current stock price is kr24.50. Egetis Therapeutics AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr0.00. Egetis Therapeutics AB's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Egetis Therapeutics AB was 5.28. The lowest was 0.77. And the median was 1.49.


Egetis Therapeutics AB Cyclically Adjusted Book per Share Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted Book per Share Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PB Ratio falls into.


;
;

Egetis Therapeutics AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egetis Therapeutics AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=15.886/132.8245*132.8245
=15.886

Current CPI (Mar. 2025) = 132.8245.

Egetis Therapeutics AB Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.503 99.995 3.325
201509 2.084 100.228 2.762
201512 1.761 100.276 2.333
201603 1.510 100.751 1.991
201606 1.071 101.019 1.408
201609 0.780 101.138 1.024
201612 14.283 102.022 18.595
201703 13.832 102.022 18.008
201706 13.287 102.752 17.176
201709 12.292 103.279 15.808
201712 11.135 103.793 14.250
201803 10.555 103.962 13.485
201806 9.521 104.875 12.058
201809 8.854 105.679 11.128
201812 8.043 105.912 10.087
201903 8.889 105.886 11.150
201906 10.991 106.742 13.677
201909 9.822 107.214 12.168
201912 8.978 107.766 11.066
202003 7.408 106.563 9.234
202006 6.086 107.498 7.520
202009 5.185 107.635 6.398
202012 23.125 108.296 28.363
202103 22.383 108.360 27.437
202106 21.133 108.928 25.769
202109 20.327 110.338 24.470
202112 19.322 112.486 22.816
202203 18.297 114.825 21.165
202206 23.280 118.384 26.120
202209 21.360 122.296 23.199
202212 18.559 126.365 19.508
202303 23.050 127.042 24.099
202306 20.198 129.407 20.731
202309 17.122 130.224 17.464
202312 20.004 131.912 20.142
202403 17.327 132.205 17.408
202406 14.720 132.716 14.732
202409 11.681 132.304 11.727
202412 18.068 132.987 18.046
202503 15.886 132.825 15.886

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Egetis Therapeutics AB  (OSTO:PLED BTA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Egetis Therapeutics AB was 5.28. The lowest was 0.77. And the median was 1.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Egetis Therapeutics AB Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines